ERBB2 and breast carcinoma: In a group of 101 node-negative patients with primary breast cancer of sizes T1 and T2 without systemic treatment in the adjuvant setting, established pathological and clinical parameters (tumour size, histological grade, steroid hormone receptor status, age and menopausal status) and HER-2/neu-related parameters (HER2_AMP, HER2_SCO, HER2_ALG and HER2_COM) were assessed and are presented in Table 1; 36% of the patients were premenopausal and perimenopausal.